QQ客服 官方微博 反馈留言

	Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep)
	Xu, J.; Shen, L.; Zhou, Z.; Li, J.; Bai, C.; Chi, Y.; Li, Z.; Xu, N.; Jia, R.; Li, E.
	2019
会议名称	44th Congress of the European-Society-for-Medical-Oncology (ESMO)
会议日期	SEP 27-OCT 01, 2019
卷号	30
页码	911-911
收录类别	CPCI-S ; SCIE
会议录	ANNALS OF ONCOLOGY
URL标识	查看原文
内容类型	会议论文
URI标识	http://www.corc.org.cn/handle/1471x/6024570
专题	山东大学
作者单位	1.Gen Hosp Peoples Liberat Army, Dept Gastrointestinal Oncol, Med Ctr 5, Beijing, Peoples R China. 2.Peking Univ C
推荐引用方式 GB/T 7714	Xu, J.,Shen, L.,Zhou, Z.,et al. Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep)[C]. 见:44th Congress of the European-Society-for-Medical-Oncology (ESMO). SEP 27-OCT 01, 2019.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。